Colorectal cancers tumor progression

Recombinant human/mouse MoAB that binds to the EGFR and inhibits the binding of EGFR and other growth factors EGFR is overexpressed in some solid tumors such as colorectal cancer cetuximab inhibits cell cycle progression induces apoptosis may enhance the effects of some chemotherapy agents and radiation... 

Recent advances in the treatment for cancer of the colon and rectum now offer the potential to improve patient survival but for many patients, improved disease- and progression-free survival represent equally important therapeutic outcomes. Table 127-15 depicts the NCCN Practice Guidelines for chemotherapy for advanced or metastatic colorectal cancer. Although treatment approaches for metastatic colorectal cancer have been historically assessed by their ability to produce a measurable objective tumor response, which is generally believed necessary for any treatment to improve survival, the effects of therapies on survival are clinically more meaningful than their ability to induce a tumor response. However, with the availability of multiple active treatments for metastatic disease, and the likelihood that patients will receive more than one during the course of their treatment, improvements in OS with new therapies wiU be increasingly difficult to determine. 

---